Esketamine (Spravato™) Nasal Spray

Description of Procedure or Service

Esketamine (Spravato™) nasal spray is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist that is indicated, in conjunction with an oral antidepressant, for the treatment of treatment-resistant depression (TRD) in adult patients.

Major depressive disorder (MDD) is a common but serious psychiatric condition that can lead to a variety of disabling emotional and physical problems. It is a chronic illness that typically requires long-term treatment. Depressive symptoms can vary and may include persistent depressed mood, lack of pleasure (anhedonia), insomnia or hypersomnia, appetite or weight change, psychomotor agitation or retardation, decreased energy, poor concentration, feelings of hopelessness or worthlessness, and recurrent thoughts of suicide or death. Treatment typically includes a combination of pharmacotherapy and psychotherapy, and can lead to improvement in many patients. There are several classes of first-line oral antidepressant drugs available such as selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and tricyclic antidepressants; however, choice of pharmacological agent is usually patient-specific.

TRD refers to when a patient has a major depressive episode with an inadequate response to therapy of adequate dose and duration. While the definition of TRD has not been standardized, it is generally indicated by an unsatisfactory response to at least two trials of antidepressant monotherapies in a current depressive episode. Patients with TRD often do not respond to subsequent pharmacotherapy trials and frequently experience chronic depression, impaired psychosocial functioning, and poor overall health. Subsequent treatment strategies may include augmentation therapy (adding a treatment to the oral antidepressant) with second generation antidepressants and/or switching treatment (e.g., psychotherapy, electroconvulsive therapy or repetitive transcranial magnetic stimulation).

Esketamine (Spravato), the S-enantiomer of racemic ketamine, is a non-selective, non-competitive antagonist of the NMDA receptor that was approved by the U.S. Food and Drug Administration (FDA) in March 2019 in conjunction with an oral antidepressant for the treatment of TRD in adults. The mechanism by which esketamine exerts its antidepressant effect is unknown.

***Note: This Medical Policy is complex and technical. For questions concerning the technical language and/or specific clinical indications for its use, please consult your physician.

Policy

BCBSNC will provide coverage for esketamine (Spravato™) nasal spray when it is determined to be medically necessary because the medical criteria and guidelines noted below are met.
Esketamine (Spravato™) Nasal Spray

Benefits Application

This medical policy relates only to the services or supplies described herein. Please refer to the Member's Benefit Booklet for availability of benefits. Member's benefits may vary according to benefit design; therefore member benefit language should be reviewed before applying the terms of this medical policy.

When Esketamine (Spravato) Nasal Spray is covered

Initial Therapy

Esketamine (Spravato) nasal spray is considered medically necessary for the treatment of adult patients (≥18 years old) with treatment-resistant depression (TRD) when the following criteria are met:

1. The patient has a confirmed diagnosis of major depressive disorder (MDD) to include one of the following:
   a. If single-episode MDD, the duration has been ≥ 2 years, OR
   b. Recurrent MDD without psychotic features; AND
2. In the current depressive episode, the patient has had an inadequate response (≤ 25% improvement) to at least two different oral antidepressants of adequate dose and duration (typically 6 weeks); AND
3. At initiation of esketamine nasal spray, the patient has a depression symptom severity of ≥ 28 on the Montgomery-Asberg Depression Rating Scale (MADRS); AND
4. The patient is receiving esketamine nasal spray in conjunction with an oral antidepressant agent (i.e. esketamine will not be used as monotherapy); AND
5. The patient does not have any clinical contraindications to esketamine therapy (i.e. aneurysmal vascular disease or intracerebral hemorrhage); AND
6. Esketamine nasal spray is:
   a. Prescribed by a psychiatrist, AND
   b. There is physician attestation that it will be administered under direct supervision of a healthcare professional at a treatment facility that is certified through the Spravato (esketamine) REMS program.

Initial authorization: 3 months

Continuation (Maintenance) Therapy

Continuation of treatment with esketamine (Spravato) nasal spray beyond 3 months after initiation of therapy, and every 6 months thereafter, is considered medically necessary for the treatment of treatment-resistant depression (TRD) when the following criteria are met:

1. The patient is currently using esketamine nasal spray and continues to meet initial criteria; AND
2. The patient will continue therapy with an oral antidepressant agent in conjunction with esketamine nasal spray; AND
Esketamine (Spravato™) Nasal Spray

3. Using the MADRS scale, the patient has demonstrated at least a 50% reduction in depressive symptoms compared to baseline while on esketamine nasal spray therapy.

When Esketamine (Spravato) Nasal Spray is not covered

Esketamine (Spravato) nasal spray is considered investigational and therefore not covered when the above criteria are not met.

Esketamine nasal spray is considered investigational when used as an anesthetic agent.

Policy Guidelines

Spravato nasal spray is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) due to the risk of serious adverse outcomes from sedation, dissociation, and abuse and misuse. Healthcare settings must be certified in the Spravato REMS program to be able to dispense and administer Spravato nasal spray to patients who are also enrolled in the program. In addition, pharmacies must be certified in the REMS program in order to dispense Spravato nasal spray to certified healthcare settings.

The FDA has issued the following black box warnings for patients receiving intranasal esketamine (Spravato): risk for sedation and dissociation after administration, potential for abuse and misuse, availability only through a restricted program called the Spravato REMS, and increased risk of suicidal thoughts and behaviors in pediatric and young adult patients taking antidepressants.

Spravato nasal spray must be administered intranasally under direct supervision of a healthcare provider, including the administration period and the post-administration supervised 2-hour observation period. Spravato nasal spray should be administered in conjunction with an oral antidepressant.

Each Spravato device contains 28 mg of esketamine, and each nasal spray device delivers two sprays containing a total of 28 mg of esketamine. The recommended dosing regimen for Spravato includes an induction phase and a maintenance phase, see Table 1. Dosing adjustments should be made based on efficacy and tolerability, and the patient should be evaluated for evidence of therapeutic benefit at the end of the induction phase in order to determine the need for continuation of treatment.

Table 1: Spravato Recommended Dosage

<table>
<thead>
<tr>
<th>Induction Phase</th>
<th>Maintenance Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Weeks 1 to 4:</strong></td>
<td><strong>Weeks 5 to 8:</strong></td>
</tr>
<tr>
<td>Twice weekly</td>
<td>Once weekly</td>
</tr>
<tr>
<td>Day 1 initial dose: 56 mg</td>
<td>56 mg or 84 mg</td>
</tr>
<tr>
<td>Subsequent doses: 56 mg or 84 mg</td>
<td>56 mg or 84 mg</td>
</tr>
<tr>
<td><strong>Week 9 and after:</strong></td>
<td><strong>Every 2 weeks or once weekly</strong></td>
</tr>
<tr>
<td>Every 2 weeks or once weekly*</td>
<td>56 mg or 84 mg</td>
</tr>
</tbody>
</table>

*Dosing frequency should be individualized to the least frequent dosing necessary to maintain remission/response
The patient’s blood pressure (BP) should be assessed prior to and after administration of Spravato nasal spray. If the baseline BP is elevated (e.g., >140 mmHg systolic, >90 mmHg diastolic), the risks of short term BP increases should be assessed compared to the benefit of Spravato treatment for the patient. Spravato should not be administered if an increase in BP or intracranial pressure poses a serious risk for the patient. BP should be reassessed approximately 40 minutes after Spravato administration, and if decreasing and the patient is clinically stable for at least 2 hours post-administration, the patient may be discharged.

Spravato is contraindicated in patients for whom an increase in BP or intracranial pressure poses a serious risk, such as aneurysmal vascular disease (including thoracic and abdominal aorta, intracranial, and peripheral arterial vessels) or arteriovenous malformation, or history of intracerebral hemorrhage.

Esketamine (Spravato) nasal spray is not approved as an anesthetic agent, as the safety and efficacy of esketamine nasal spray have not been established for use as an anesthetic agent. Esketamine nasal spray is not approved for use in pediatric patients.

The Montgomery-Asberg Depression Rating Scale (MADRS) scoring system consists of a ten-item, clinician-rated scale that is used to evaluate the severity of core depressive symptoms. The total score on the MADRS scale ranges from 0 to 60, with higher scores indicating more severe depression.

Clinical Trial Evidence

The efficacy and safety of esketamine (Spravato) nasal spray in conjunction with an oral antidepressant (AD) for the treatment of treatment-resistant depression (TRD) has been evaluated in both short-term and long-term studies.

The efficacy and safety of intranasal esketamine (Spravato) plus an oral AD for the treatment of adult patients with TRD was evaluated in a randomized, placebo-controlled, double-blind, multicenter, short-term (4-week), phase 3 study (Study 1; NCT02418585). Patients included in the trial (n=236) met DSM-5 (Diagnostic and Statistical Manual of Mental Disorders) diagnostic criteria for major depressive disorder (MDD) and, in the current depressive episode, had not responded adequately (≤ 25% improvement) to at least two different oral ADs of adequate dose and duration. Patients enrolled in the trial must also have a current major depressive episode symptom severity defined by a MADRS total score of ≥ 28 at week 1. Following discontinuation of prior AD treatments, study participants were randomized to receive twice weekly dosing of Spravato nasal spray (flexible dose; 56 mg or 84 mg) or intranasal placebo. Additionally, all patients also received open-label concurrent treatment with a newly initiated daily oral AD (duloxetine, escitalopram, sertraline, or extended-release venlafaxine). The Spravato dose could be titrated up to 84 mg per investigator discretion beginning with the second dose. The primary efficacy endpoint was change from baseline in MADRS total score at the end of the 4-week double-blind induction phase. The least-squares mean difference in MADRS score between the two treatment groups was 4.0 (95% CI, -7.3; -0.6). Treatment with Spravato plus a newly initiated oral AD showed statistical superiority for the primary efficacy endpoint compared to intranasal placebo plus a newly initiated oral AD.

The efficacy of intranasal esketamine (Spravato) plus an oral AD in delaying relapse of depressive symptoms in TRD was also evaluated in a long-term randomized, double-blind, parallel-group, multicenter, maintenance-of-effect trial of 703 adult patients who were known remitters and responders to Spravato (Study 2; NCT02493868). Patients enrolled in Study 2 were either responders in one of two short-term controlled trials (Study 1 and another 4-week study) or...
Esketamine (Spravato™) Nasal Spray

in an open-label direct-enrollment study in which they received flexible dosing of Spravato (56 mg or 84 mg twice weekly) plus a daily oral AD in an initial 4-week phase. Within the study, stable remission was defined as a MADRS total score of ≤ 12 for at least 3 of the last 4 weeks, and stable response was defined as a MADRS total score reduction of ≥ 50% for the last 2 weeks of optimization and not in remission. Following at least 16 initial weeks of Spravato treatment plus an oral AD, stable remitters and stable responders were randomized separately to continue receiving Spravato nasal spray or to switch to intranasal placebo, with each group continuing concomitant therapy with an oral AD. The primary efficacy endpoint was time to relapse in patients with stable remission. Relapse was defined within the study as a MADRS total score of ≥ 22 for 2 consecutive weeks or hospitalization for worsening depression or any other clinically relevant event indicating relapse. Patients in stable remission who continued treatment with Spravato nasal spray plus an oral AD demonstrated a statistically significant longer time to relapse of depressive symptoms than patients receiving intranasal placebo plus an oral AD.

The following information is derived from FDA prescribing information, as peer reviewed published trial results have not been identified.

Billing/Coding/Physician Documentation Information

This policy may apply to the following codes. Inclusion of a code in this section does not guarantee that it will be reimbursed. For further information on reimbursement guidelines, please see Administrative Policies on the Blue Cross Blue Shield of North Carolina web site at www.bcbsnc.com. They are listed in the Category Search on the Medical Policy search page.

Applicable codes: J3490

BCBSNC may request medical records for determination of medical necessity. When medical records are requested, letters of support and/or explanation are often useful, but are not sufficient documentation unless all specific information needed to make a medical necessity determination is included.

Scientific Background and Reference Sources


Medical Director review 5/2019

Policy Implementation/Update Information
Esketamine (Spravato™) Nasal Spray

5/28/19  New policy developed. Spravato nasal spray is considered medically necessary for the treatment of adult patients (≥18 years old) with treatment-resistant depression. Added HCPCS code J3490 to Billing/Coding section. References added. Medical Director review 5/2019. (krc)

Medical policy is not an authorization, certification, explanation of benefits or a contract. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the group contract and subscriber certificate that is in effect at the time services are rendered. This document is solely provided for informational purposes only and is based on research of current medical literature and review of common medical practices in the treatment and diagnosis of disease. Medical practices and knowledge are constantly changing and BCBSNC reserves the right to review and revise its medical policies periodically.